Jonathan Fleming

Senior Lecturer, Trust Center for MIT Entrepreneurship


Jonathan Fleming

Jonathan Fleming is a Senior Lecturer in the Martin Trust Center for MIT Entrepreneurship at the MIT Sloan School of Management.

Fleming is a general partner of Oxford Bioscience Partners (OBP), an international venture capital firm specializing in life science technology based investments, with offices in Boston and Connecticut. He has worked in the investment business for more than 20 years, starting and financing growth companies in the United States, Europe, and Israel. Prior to joining OBP in 1996, he was a founding general partner of MVP Ventures in Boston. He began his investment career with TVM Techno Venture Management in Munich, Germany. Fleming also co-founded Medica Venture Partners, a venture capital investment firm specializing in early stage healthcare and biotechnology companies in Israel. Fleming serves on the board of Asterand plc and is a director of several private companies, including Leerink Swann, a Boston-based investment bank specializing in healthcare companies. He is a trustee of the Museum of Science, Boston, and a member of the board of the New England Healthcare Institute.

Fleming holds a BA from the University of California, Berkeley, and a master’s degree in public administration from Princeton University.



Contact Information
Tel: (617) 357-7474
Fax: 617-253-8633

Research Center(s)

General Expertise
$100K Entrepreneurship Competition; Alliances; Analyst forecasts; Angel investing; Applied economics; Biopharmaceutical; Biotechnology; Business plans; Cancer, multi-drug therapy models; Capital budgeting; Capital market; CEO compensation; Corporate diversification; Corporate finance; Corporate governance; Economic history; Economics; Economics of organizations; Emerging businesses; Entrepreneurial finance; Entrepreneurship / New ventures; Euro; Federal Reserve; Finance; Financial engineering; Financial reporting; Foreign investment; Genetics; Germany; Health management; Healthcare industry; Hedge funds; HIV, multi-drug therapy models; Industrial economics; Investment analysis; Knowledge management; Medical devices; Medicine; Mergers and acquisitions; Microeconomics; Middle East; New ventures; Patents; Political economy; Research and development; Sarbanes-Oxley compliance; Startups; Technological innovation; Venture capital